Send to

Choose Destination
See comment in PubMed Commons below
Neurosci Behav Physiol. 2009 Mar;39(3):305-9. doi: 10.1007/s11055-009-9127-5.

Experience of the use of velaxin (venlafaxine) in anxious depression.

Author information

Scientific Center for Mental Health, Russian Academy of Medical Sciences, Moscow, Russia.


Thirty patients (seven men and 23 women, mean age 35.3 +/- 7.8 years) with anxious and anxious-apathic depression were studied. Of these, 24 patients were treated in hospital and six in out-patient clinics. Patients were treated for eight weeks with venlafaxine at doses of 225-375 mg/day. Mental state was assessed using a series of scales (CGI, HDRS, BDI, HADS-21). A total of 27 patients (90%) completed treatment. There were 25 (83.3%) responders on the CGI scale: "improvement" in mental state occurred in 16 (59.3%) of patients and "marked improvement" occurred in nine (33.3%). "Insignificant improvement" was seen in two cases (7.4%). Complete elimination of symptoms of depression occurred in 33.3% of cases. Velaxin was found to be safe at intermediate therapeutic doses and there were improvements in laboratory results characterizing patients' somatic status.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center